glp-1 and diabetes GLP-1-based therapies for type 2 diabetes: from single, dual triple agonists to endogenous production and L-cell differentiation | Diabetology & Metabolic Syndrome GLP-1 trends 2025: real-world data,

Every person evaluating any compounded GLP-1 program - IVY RX included - should understand this before enrolling

research found a 20 percent reduction in cardiovascular events (stroke and heart attacks) over a three-year period in a high-risk group

Several previous studies have revealed possible mechanisms for nervous system damage, including mitochondrial damage and associated inflammation in nerve cells 2 , 3

The first patients of these medications were people with Type 2 diabetes, as their main purpose is to assist in the management of blood sugar (glucose) levels

Moreover, peptide analogues that are unimolecular co-agonists of both GLP-1R and GCGR are currently in clinical development for the treatment of T2D, obesity and non-alcoholic steatohepatitis (NASH) 2,3,5,6,7